262 related articles for article (PubMed ID: 10798762)
1. Lamivudine for hepatitis B in liver transplantation: a single-center experience.
Malkan G; Cattral MS; Humar A; Al Asghar H; Greig PD; Hemming AW; Levy GA; Lilly LB
Transplantation; 2000 Apr; 69(7):1403-7. PubMed ID: 10798762
[TBL] [Abstract][Full Text] [Related]
2. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
[TBL] [Abstract][Full Text] [Related]
3. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.
Markowitz JS; Martin P; Conrad AJ; Markmann JF; Seu P; Yersiz H; Goss JA; Schmidt P; Pakrasi A; Artinian L; Murray NG; Imagawa DK; Holt C; Goldstein LI; Stribling R; Busuttil RW
Hepatology; 1998 Aug; 28(2):585-9. PubMed ID: 9696028
[TBL] [Abstract][Full Text] [Related]
5. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.
Seehofer D; Rayes N; Steinmüller T; Müller AR; Jonas S; Settmacher U; Neuhaus R; Berg T; Neuhaus P
Z Gastroenterol; 2002 Sep; 40(9):795-9. PubMed ID: 12215948
[TBL] [Abstract][Full Text] [Related]
6. Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature.
Ben-Ari Z; Mor E; Tur-Kaspa R
J Intern Med; 2003 May; 253(5):544-52. PubMed ID: 12702032
[TBL] [Abstract][Full Text] [Related]
7. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
[TBL] [Abstract][Full Text] [Related]
8. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
Vizzini G; Gruttadauria S; Volpes R; D'Antoni A; Pietrosi G; Filì D; Petridis I; Pagano D; Tuzzolino F; Santonocito MM; Gridelli B
Clin Transplant; 2011; 25(1):E77-81. PubMed ID: 21039887
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience.
Murakami R; Amada N; Sato T; Orii T; Kikuchi H; Haga I; Ohashi Y; Okazaki H
Clin Transplant; 2006; 20(3):351-8. PubMed ID: 16824154
[TBL] [Abstract][Full Text] [Related]
10. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin.
McCaughan GW; Spencer J; Koorey D; Bowden S; Bartholomeusz A; Littlejohn M; Verran D; Chui AK; Sheil AG; Jones RM; Locarnini SA; Angus PW
Liver Transpl Surg; 1999 Nov; 5(6):512-9. PubMed ID: 10545540
[TBL] [Abstract][Full Text] [Related]
11. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.
Lu SC; Yan LN; Li B; Wen TF; Zhao JC; Cheng NS; Liu C; Liu J; Wang XB; Li XD; Qin S; Zhao LS; Lei BJ; Zhang XH
Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):26-32. PubMed ID: 14969833
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
Huang YW; Liu CJ; Lai MY; Lee PH; Tsai MK; Wang SS; Lai MK; Kao JH
Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
Marzano A; Lampertico P; Mazzaferro V; Carenzi S; Vigano M; Romito R; Pulvirenti A; Franchello A; Colombo M; Salizzoni M; Rizzetto M
Liver Transpl; 2005 May; 11(5):532-8. PubMed ID: 15838891
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation.
Ben-Ari Z; Zemel R; Kazetsker A; Fraser G; Tur-Kaspa R
Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation.
Andreone P; Biselli M; Gramenzi A; Cursaro C; Morelli MC; Sama C; Lorenzini S; Spinucci G; Porzio F; Felline F; Di Giammarino L; Bernardi M
Transplantation; 2002 Oct; 74(8):1119-24. PubMed ID: 12438957
[TBL] [Abstract][Full Text] [Related]
18. Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence.
Han DJ; Kim TH; Park SK; Lee SK; Kim SB; Yang WS; Park JS; Jung JG; Yu ES; Kim SC
Transplantation; 2001 Feb; 71(3):387-94. PubMed ID: 11233898
[TBL] [Abstract][Full Text] [Related]
19. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
Chan TM; Fang GX; Tang CS; Cheng IK; Lai KN; Ho SK
Hepatology; 2002 Nov; 36(5):1246-52. PubMed ID: 12395336
[TBL] [Abstract][Full Text] [Related]
20. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
